{
    "nctId": "NCT00291577",
    "briefTitle": "Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer",
    "officialTitle": "Exploratory Evaluation Of A Sequential Administration Of Docetaxel And SU011248 In Women With Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 22,
    "primaryOutcomeMeasure": "Time to Reach Maximum Plasma Concentration (Tmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Breast cancer with evidence of unresectable, locally recurrent or metastatic disease\n* Candidate for treatment with docetaxel\n\nExclusion Criteria:\n\n* Prior chemotherapy in the advanced disease setting\n* Inflammatory breast cancer\n* HER2 positive disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}